hepatitis b virus n.
Skip this Video
Loading SlideShow in 5 Seconds..
HEPATITIS B VIRUS PowerPoint Presentation
Download Presentation

Loading in 2 Seconds...

play fullscreen
1 / 41

HEPATITIS B VIRUS - PowerPoint PPT Presentation

  • Uploaded on

HEPATITIS B VIRUS. Presented by Group I PCL2. MEMBERS OF GROUP BAHIZI Sadallah Ug 12114376 BAMPORIKI Judith Ug 12214657 BAYINGANA Marie Eve Ug 12214674 BAZAMBAZA Philippe Ug 12215192

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'HEPATITIS B VIRUS' - farren

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
hepatitis b virus


Presented by Group I PCL2



BAHIZI SadallahUg12114376

BAMPORIKI Judith Ug 12214657

BAYINGANA Marie Eve Ug 12214674

BAZAMBAZA Philippe Ug 12215192

BITUNGURAMYE Adam Ug 12114056

BIZIMANA Anselme UG12114504

BUGINGO JEAN Pierre Ug 12113855

BUHOLO Jael Ug12214676

BUSOMOKE Denys FabriceUg 12113988

BYIRINGIRO Jean d’ Amour Ug 12113049

CHOI Jaeseok Ug12215093`

MUPIKA MedaUg12214675

c ontent
  • Introduction
  • Epidemiology
  • Pathogenesis
  • Clinical manifestation
  • Diagnosis
  • Treatment
  • Prevention
1 introduction
1. Introduction
  • The early evolution of the Hepatitis B is difficult to establish.The divergence of orthohepadnavirus occurred ~125,000 years ago. Orthohepadna viruses began to diversify about 25,000 years ago. Hepatitis B Virus (HBV) is a member of the hepadnavirus family. It is a 42-nm envelopedvirion, with an icosahedralnucleocapsid core containing a partially double-stranded circular DNA genome.
  • Year of identification 1965

The virus is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenicepitopes present on its envelope proteins, and into eight genotypes (A-H) according to overall nucleotide sequence variation of the genome


The genome of HBV is a partially double-stranded circular DNA molecule

  • A nucleocapsid “core” protein (HBcAg, Hepatitis B core antigen) and a longer polypeptide transcript with a precore and core region, designated HBeAg (Hepatitis B “e” antigen). The precore region directs the HBeAg polypeptide toward secretion into blood, whereas HBcAg remains in hepatocytes for the assembly of complete virions.
  • Envelope glycoproteins (HBsAg, Hepatitis B surface antigen), which consist of three related proteins:

large HBsAg (containing Pre-S1, Pre-S2, and S), middle HBsAg (containing Pre-S2 and S), and small HBsAg (containing S only).

Infected hepatocytes are capable of synthesizing and secreting massive quantities of noninfective surface protein (mainly small HBsAg).

  • The DNA polymerase is encoded by gene P. A polymerase (Pol) that exhibits both DNA polymerase activity and reverse transcriptase activity. Genomic replication occurs via an intermediate RNA template, through a unique replication cycle: DNA ➙ RNA ➙ DNA.
  • HBx protein, which is necessary for virus replication and may act as a transcriptional transactivator of the viral genes and a wide variety of host genes. It has been implicated in the pathogenesis of liver cancer in HBV infection.

Electron microscopy of a patient's serum reveals three different types of particles: a few 42-nm virions and many 22-nm spheres and long filaments 22 nm wide, which are composed of surface antigen

2 epidemiology
2. Epidemiology

There are three important modes of transmission of HBV infection:

  • Parenteral (usage of contaminated needles and syringes, intravenous drug abuse,…)
  • Perinatal(can be transmitted from carrier mothers to their babies during the perinatal period
  • Sexual(is present in semen and vaginal secretions)
  • High Endemicity: prevalence in developing regions with large population such as South East Asia, China, sub-Saharan Africa and the Amazon Basin, where at least 8% of the population are HBV chronic carrier.
  • Intermediate Endemicity: moderately endemic in part of Eastern and Southern Europe, the Middle East, Japan, and part of South America, and 2-7% are chronic carriers
  • Low Endemicity: low in most developed areas, such as North America, Northern and Western Europe and Australia, 0.5–2% of the population are chronic carriers.

About 5-10% of HBV infections result in chronic carrier state. The latter may be defined as persistence of HBsAg in the circulation for more than six months.

Carriers are of two types:

  • Super carriers: They have HBeAg, high titres of HBsAg and DNA polymerase in their blood. HBV may also be demonstrable in their blood. Very minute amount of serum or blood from such carriers can transmit the infection.
  • Simple carriers: These are more common types of carriers who have low level of HBsAg and no HBeAg, HBV and DNA polymerase in the blood. They transmit the infection only when large volumes of blood are transferred as in blood transfusion.
3 pathogenesis
3. Pathogenesis
  • The virus replicates in the liver
  • Viruses are released into blood circulation
  • The blood become highly infectious
  • 5% of infected individuals fail to eliminate the virus

and become persistently infected

  • T-cells response eliminates viral infected liver cells during acute hepatitis B in more than 90%
  • Host immunological response is thought to be behind the liver injury for the following reasons:

-The existence of HBV carriers with normal liver histology and function

-Patient with defects in cellular immune competence are more likely to remain chronically infected.


The replication cycle of HBV

DNA Genomes replicated by reverse transcription

  • Begins with attachment of the virion to the hepatocyte membrane
  • The exact mechanisms of virus attachment are not clear but are thought to be mediated through the pre-S1 region of the virion envelope
  • The virion is uncoated in the hepatocyte cytoplasm and the viral genome enters the hepatocyte nucleus
  • Nucleocapsids with the partially double stranded HBV DNA can reenter the hepatocyte nucleus to produce more ccc DNA or be secreted as complete virions after coating with envelope proteins.
  • The ccc DNA appears to have a long half-life and is very resistant to antiviral therapy, accounting for the difficulty in achieving virus clearance during treatment of chronic hepatitis B.
  • Mutations in all regions of HBV have been found in patients with chronic HBV infection.
  • Some of these mutations, such as the precore stop codon mutation, have been incriminated in causing more severe liver disease
  • However, these variants have also been found in asymptomatic carriers , suggesting that the mutations alone are not necessarily pathogenic.
  • Nevertheless, HBV mutations can potentially modulate the severity of liver disease by altering the level of HBV replication or the expression of immunogenic epitopes
  • The primary cause of hepatic cell destruction appears to be the cell-mediated immune response. The cells involved are HLA-I- restricted cytotoxic T cells, which react specifically with the fragments of nucleocapsid proteins, HBcAg and HBeAg, expressed on the surface of infected hepatocytes.
attachment penetration and uncoating
Attachment, Penetration, and Uncoating

Attachment Endocytosis Penetration Uncoating

Figure 13.14


In brief of replication:

  • Early phase include
  • Recognition of the target cell
  • Attachment
  • Penetration
  • Uncoating
  • Late phase include
  • Macromolecular synthesis ( transcription, DNA Genomes replicated by reverse transcription, translation,…)
  • Auto assembly virus
  • Release of virus
multiplication of dna virus of hbv
Multiplication of DNA Virus of HBV



Virion attaches to host cell


Virions are released

Host cell





Virion penetrates cell and its DNA is uncoated



Virions mature

Capsid proteins



Late translation; capsid proteins are synthesized



Late transcription; DNA is replicated

Early transcription and translation; enzymes are synthesized

Figure 13.15

4 clinical manifestation
4. Clinical manifestation
  • The prodromal symptoms of acute viral hepatitis: anorexia, nausea, headache, vomiting, fatigue, fever of 39.5°–40°C and jaundice
  • Upper right quadrant pain
  • Some change in dark urine and pale feces

The natural course of the disease can be followed by serum markers

FIGURE 18-11( from Robbins &Cotran Pathology,8thed ) below show Sequence of serologic markers for hepatitis B viral hepatitis demonstrating (A) acute infection with resolution and (B) progression to chronic infection.

5 diagnosis
5. Diagnosis

The most important laboratory test for the detection of HBV infection:

  • Immunoassay for HBsAg is detectable in most patients during the prodrome and acute disease and undetectable at least 6 months
  • PCR analysis where DNA can be detected

HBsAbis undetectable because it is bound in immune complexes and DNA polymerase activity is detectable during the incubation period and early in the disease, but the assay is not available in most clinical laboratories

6 treatment
6. Treatment
  • Acute infection

Acute infection with hepatitis B usually does not require treatment. In rare cases, however, the infection may cause life-threatening liver failure. Patients with liver failure due to acute hepatitis B should be evaluated for liver transplantation. Small studies suggest that the drug lamivudine (Epivir) may be effective in this setting.

  • Chronic infection

If a person is chronically infected with hepatitis B and has few signs or symptoms of complications, medications usually are not used. These patients are watched carefully and given periodic blood tests


The medications in current use for chronic hepatitis B include the interferons and nucleoside/nucleotide analogues

  • Interferon-alpaHas been used to treat hepatitis B for more than 20 years. Interferon-alpha is a naturally occurring protein that is made in the body by white blood cells to combat viral infections. In addition to its direct anti-viral effects, interferon works against the hepatitis B virus by stimulating the body's immune system to clear the virus.
  • Nucleoside/nucleotide analogues (NAs)

Are man-made chemicals that mimic the nucleosides and nucleotides that are used for making DNA. When the virus tries to use the analogues to make its own DNA, it is unable to make the DNA and, therefore, cannot reproduce. Examples of these agents include adefovir (Hepsera), entecavir (Baraclude), lamivudine (Epivir-HBV, Heptovir, Heptodin), telbivudine (Tyzeka) and tenofovir (Viread).

7 prevention
7. Prevention
  • Behavior Modification

Changes in sexual practice and improved screening measures of blood products have reduced the risk of transfusion-associated hepatitis.

  • Postexposure (Passive immunization)

Hepatitis B Immune Globulin (HBIG) is a sterile solution of ready-made antibodies against hepatitis B is used

  • newborns of mothers infected with hepatitis B
  • After needlestick exposure
  • After sexual exposure
  • After liver transplantatio
  • Preexposure (Active immunization)

Prevention of primary infection by vaccination is an important strategy to decrease the risk of chronic HBV infection and its subsequent complications.

The vaccine is prepared from purified HbsAg produced in yeast. Vaccination induces a protective anti-HBs antibody response in 95% of infants, children, and adolescents.

A vaccine called Twinrixthat contains both HBsAg and inactivated HAV provides protection against both hepatitis B.

8 reference
8. Reference
  • http://www.medicinenet.com
  • Professor note document
  • Lange Microbiology and Immunology review 10 editions
  • Robbins & pathology Basic of Disease, 8 editions
  • UPtoDATE 2011